T

Tidalsense

www.tidalsense.com link_icon

TidalSense Company Research Report



Company Overview


Name


TidalSense (formerly known as Cambridge Respiratory Innovations)

Mission


Transforming respiratory care pathways with AI-driven diagnostic and monitoring technologies.

Founded and Founders


  • Founded: 2013

  • Founder: Dr. Julian Carter, PhD


Key People


  • Chief Executive Officer: Dr. Ameera Patel, MD PhD

  • Director of Engineering: Dr. Julian Carter, PhD

  • Commercial Director: Mark Gleeson, MBA

  • Chief Financial Officer: Christian Faires, CGMA ACMA


Headquarters


The Vinery, 15a Vinery Road, Cambridge, CB1 3DN, United Kingdom

Number of Employees


No information is available.

Revenue


No information is available.

Known For


TidalSense is known for its AI-driven diagnostic and monitoring technologies for chronic obstructive pulmonary disease (COPD) and asthma.

Products


Overview


TidalSense offers a range of products under the N-Tidal™ platform for diagnosing, monitoring, and improving respiratory health.

Products



N-Tidal™


A powerful platform offering diagnostic and monitoring solutions through a best-in-class sensor and AI-driven technologies.

N-Tidal Capture™


  • Description: CE-marked, remote patient monitoring solution for obstructive airway conditions such as asthma and COPD.

  • Key Features:

  • Real-time access to N-Tidal biomarkers via clinical dashboard.

  • Data automatically uploaded and processed in real-time.

  • Longitudinal patient data visualization for clinicians.


N-Tidal Diagnose™


  • Description: Point-of-care diagnostic solution for COPD and asthma.

  • Key Features:

  • Diagnostic AI interprets respiratory biomarkers in real-time.

  • Under 5 minutes from test to diagnosis.

  • Usable by healthcare assistants, nurses, and doctors with minimal training.


Unique Sensor


  • Features:

  • Patented, industry-leading sensor developed over 10 years.

  • Utilized in clinical trials.

  • Turns breaths into sensitive N-Tidal lung biomarkers.


AI Engine


  • Features:

  • Real-time biomarker generation on the cloud.

  • End-to-end automation transforming breaths into real-time biomarkers.


Recent Developments


New Products Launched


  • N-Tidal Diagnose™: To be launched soon, currently available for registration of interest.


New Features Added


  • Continuous improvement of AI diagnostic algorithms and incorporation of novel biomarkers.


New Partnerships


  • Validation of AI diagnostic technology in a real-world setting: In collaboration with Asthma + Lung UK, Chiesi Limited, Hull York Medical School, and Hull University Teaching Hospitals NHS Trust.

  • Study on early COPD detection: Supported by a grant from Asthma + Lung UK and is aimed at facilitating early diagnosis using TidalSense technology.


Press Releases


  • 7 November 2023: Collaboration with Asthma + Lung UK and other partners to address UK's respiratory diagnostic crisis.

  • Funding: Received a substantial £287,000 grant from Asthma + Lung UK for COPD diagnostic technology validation.

  • Clinical Studies: Continuous efforts in collecting over 2.5 million patient breaths, driving diagnostic AI algorithms, and conducting usability studies.


Contact Information


Address


The Vinery, 15a Vinery Road, Cambridge, CB1 3DN, United Kingdom

Social Media






Press Inquiries


  • Email: press@tidalsense.com